The grant covered continued funding of the SGCDL from July 1, 2017 through June 30, 2019. The lab has been under continuous operation since mid-2006 and has run over 350,000 samples since its inception. Sample results have been kept confidential with reports only being released to the sample submitter. Over the two-year grant period, 49,362 samples were run (down from 63,486 for the previous funding period). Of the samples run, 95% were plant samples (mostly leaves but some roots) and 5% were psyllid samples. Approximately 58% of the samples were run during year 1 of the funding (28,478) and 42% were run during year 2 of the funding (20,488). The great majority of the samples were from research trials. The fact that most of the samples were from research trials is similar to the previous funding cycle but represents a change from the early years where the samples were primarily diagnostic in nature. Since the samples were from trials, sample submissions tended to come in based on the timing required in the trial (i.e. twice a year, quarterly, monthly, etc.). Also depending on the trials, the samples tended to come in as large groups as opposed to individual small lots of samples. At times, samples arrived in groups of a 500 or more. This made scheduling a little difficult as the lab never knew when and how many samples were going to arrive. Thus sample turnaround varied from less than a week to up to 4-6 weeks depending on the sample load.During the previous funding period and continuing this funding period, and at the request of the customers, the SGCDL began quantifying the amount of DNA in the sample and running a standard curve in order to provide copy number in addition to the raw CT values. As time progressed, more and more of the samples were reported in this matter. For the current funding period, copy number was reported on approximately 50% of the outside samples (does not include internal Southern Gardens samples). The reduction in sample during the funding period is in part due to the effects of Hurricane Irma (which changed the planned sampling for many trials) and to a decline in the sampling of some of the CRDF trials, which traditionally has been the largest customer of the laboratory.